Search Results
Your search for all items matches 36965 pages
Showing 1 - 50Building Momentum: ASCO’s Geriatric Oncology CoP
The ASCO Geriatric Oncology Community of Practice (geriatric oncology CoP) convened for its first in-person meeting at McCormick Place in Chicago in May 2026. Since its inception in 2022, the geriatric oncology CoP has brought together clinicians, researchers, trainees, and patient advocates...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
Guideline Update Recommends Tailoring Breast Cancer Surveillance Based on Recurrence Risk
ASCO has published a guideline update offering clinicians new recommendations for breast cancer follow-up and surveillance after primary treatment.1 For this patient population, determining the optimal frequency and timing of visits can be a challenge, according to Expert Panel Co-Chair Maryam...
Jonathan W. Goldman, MD, on SCLC: Tarlatamab Extended-Interval Dosing Regimens
Jonathan W. Goldman, MD, of the University of California, Los Angeles, reviews findings from the phase II DeLLphi-309 study, which examined the efficacy, safety, and pharmacokinetics of tarlatamab extended-interval dosing regimens (20 mg every 3 weeks and 30 mg every 4 weeks) in comparison to the...
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
A multi-cancer early detection test named Galleri from the health-care company GRAIL received a favorable vote from the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee. The Committee voted for approval of the premarket...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
A multimodal artificial intelligence (AI) model incorporating multiscale histopathology features was able to predict recurrence risk in patients with early-stage hormone receptor–positive and HER2-negative breast cancer more accurately than the 21-gene recurrence score, Oncotype DX, according to...
How One Nonprofit Is Providing Access to a Discontinued Investigational Drug for Children With a Rare Form of AML
Blood Cancer United (formerly the Leukemia & Lymphoma Society) recently announced it had acquired the remaining supply and rights to the investigational agent luveltamab tazevibulin, an antibody drug conjugate targeting the folate receptor-1 alpha (FOLR1) molecule, from the drug’s manufacturer, ...
As AI Advances, How Will the Clinician’s Role Change?
Peter Clardy, MD, of Google for Health, described a fundamental challenge facing clinicians in the artificial intelligence (AI) era: AI capabilities are advancing rapidly at the same time clinicians are being asked to make decisions based on an ever-expanding volume of information. In oncology...
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
New updates to the College of American Pathologists’ (CAP) Cancer Protocols will affect breast cancer biomarker reporting and molecular testing for gastrointestinal stromal tumors (GISTs), reflecting advances in precision oncology and laboratory accreditation. The updates are part of revisions to...
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were...
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
The B7-H3–targeting antibody-drug conjugate tambotatug pelitecan significantly improved overall survival compared with topotecan in patients with small cell lung cancer (SCLC) that had progressed after first-line platinum-based therapy, according to results of the phase III TAISHAN-302 trial...
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
On September 23, 2026, the U.S. Food and Drug Administration (FDA) approved lirafugratinib (Lyrfigtu) for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other...
Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer
The human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate trastuzumab rezetecan significantly improved progression-free survival and produced higher response rates compared with standard-of-care therapy in patients with chemotherapy-refractory, HER2-positive, RAS/RAF...
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Adding venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) did not improve progression-free survival and resulted in excess toxicity and mortality among patients with newly diagnosed double-hit lymphoma, prompting early closure of the double-hit lymphoma cohort of the randomized ALLIANCE A051701...
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
Neoadjuvant treatment with the ERBB2-biparatopic antibody anbenitamab plus a solvent-free albumin-bound docetaxel formulation (HB1801) significantly improved total pathologic complete response vs conventional therapy with trastuzumab plus pertuzumab and a taxane (THP) in patients with early or...
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Researchers have found a significantly increased risk of lung cancer in individuals with an EGFR T790M germline variant, about 25 times higher than in noncarriers, according to study findings published in Science. “Today, lung cancer screening is driven almost entirely by smoking history,” said...
Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC
Patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease progressed following PD-1/-L1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti–CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving...
Julia Rotow, MD, on Metastatic HER2-Mutant NSCLC: First-Line T-DXd
Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses the primary results from the phase III DESTINY-Lung04 trial, which evaluated first-line trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, against pembrolizumab plus platinum chemotherapy in patients with...
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
Researchers have identified varying clinicopathologic characteristics and outcomes between patients with non–small cell lung cancer (NSCLC) and class II and III BRAF mutations, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World...
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
Three studies presented at the 2026 ASCO Breakthrough conference in Singapore focused on problems that can derail cancer care even when treatment is otherwise on track: nausea after starting morphine, continued smoking after a cancer diagnosis, and unrecognized frailty in older adults. Although the ...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality, and survivorship. It also outlines how basic, translational, and clinical cancer research and...
KEYNOTE-826: Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
Five-year follow-up from the phase III KEYNOTE-826 trial suggests a durable benefit with first-line pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in patients with recurrent or metastatic cervical cancer, according to Hasegawa et al in JAMA Oncology. At the first...
Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance
For many men with low-risk prostate cancer, active surveillance means living with cancer while delaying—or potentially avoiding—surgery or radiation therapy. It also leaves many patients asking what they can do beyond “wait and watch.” Findings presented at the 2026 American Urological Association...
Martin Reck, MD, PhD, on Resectable/Borderline Resectable NSCLC: Neoadjuvant Durvalumab Plus Chemotherapy
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, reviews efficacy and safety data from the primary analysis of MDT-BRIDGE. The phase II study is investigating perioperative durvalumab plus neoadjuvant chemotherapy in patients with resectable/borderline resectable stage IIB–IIIB non–small cell...
Mobile CT Lung Cancer Screening May Expand Access for Underserved Populations
Mobile low-dose computed tomography (LDCT) screening may be able to reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of...
ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer
For appropriately selected patients with muscle-invasive bladder cancer, bladder preservation can be a curative treatment option, according to a new clinical guideline from the American Society for Radiation Oncology (ASTRO). The recommendations support trimodal therapy (maximal transurethral...
Losing Weight and Breast Cancer Risk? The GLP-1 Question
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity and diabetes has sparked interest in their potential effects on breast cancer risk and outcomes. At the 2026 ASCO Annual Meeting, investigators presented several observational studies examining the relationship...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including oral triple metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On September 18, the U.S. Food and Drug Administration (FDA) approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with...
Alexander I. Spira MD, PhD, FACP, FASCO, on Metastatic EGFR-Mutated NSCLC: Global Study of Izalontamab Brenitecan
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists and US Oncology, discusses findings from a global phase I study of izalontamab brenitecan (BL-B01D1), an antibody-drug conjugate comprising an EGFR x HER3 bispecific antibody conjugated to a novel topoisomerase 1 inhibitor...
First-Line Amivantamab/Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Results from the phase III PAPILLON study show that first-line amivantamab plus carboplatin/pemetrexed (amivantamab/chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non–small cell lung cancer (NSCLC)...
Alcohol-Attributable Cancer Deaths More Than Double in the United States
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas. “Our findings highlight...
Azacitidine/Venetoclax Improves Event-Free Survival in Fit Patients With AML
Azacitidine plus venetoclax significantly prolonged event-free survival compared with intensive induction chemotherapy in previously untreated patients with acute myeloid leukemia (AML) who were eligible for induction therapy. Results of the randomized phase II PARADIGM trial, led by Fathi et al,...
Tumor Budding Grading System Can Identify High-Risk Patients With Lung Squamous Cell Carcinoma
A tumor budding–based grading system was able to successfully identify patients with resected lung squamous cell carcinoma who were at a higher risk of poor overall survival and relapse-free survival outcomes, according to findings presented at the International Association for the Study of Lung...
AI’s Evolving Role in Clinical Care Enterprise-Wide
Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland...
FDA Approves New Labeling of ROS1 Inhibitor in TKI-Naive Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has approved updated labeling of taletrectinib (Ibtrozi), an oral, CNS-active, selective next-generation ROS1 inhibitor therapy for non–small cell lung cancer (NSCLC), reflecting a median duration of response of 49.7 months in tyrosine kinase inhibitor...
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Trastuzumab deruxtecan significantly improved progression-free survival over pembrolizumab plus platinum-based chemotherapy for patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC) who were being treated in the first-line setting, according to phase III DESTINY-Lung04 ...
Zipalertinib Added to Chemotherapy Improves Progression-Free Survival in First-Line EGFR Exon 20 Mutation–Positive NSCLC
The addition of zipalertinib to platinum/pemetrexed chemotherapy led to a significant improvement in progression-free survival in patients with advanced non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation, according to phase III findings presented at the International...
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma
The 5-year follow-up of the phase II OPTIMUM/MUKnine trial found sustained improvements in progression-free and overall survival with an intensive, risk-adapted treatment strategy for patients with newly diagnosed high-risk multiple myeloma. The findings, reported by Kaiser et al in The Lancet...
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
The National Comprehensive Cancer Network® (NCCN®) has released a new resource to help patients and caregivers understand how to tailor cancer care for aging populations. “The medical advances we’ve seen in cardiology and infectious disease are a huge triumph; because we are better at treating...
Zidesamtinib Demonstrates 94% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC
New results from the global phase I/II ARROS-1 trial showed clinically meaningful activity with the ROS1 selective inhibitor zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The...
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided...
Chul Kim, MD, on NSCLC With EGFR Exon 20 Insertions: First-Line Amivantamab/Chemotherapy vs Chemotherapy
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated...
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
This September, in honor of Prostate Cancer Awareness Month, the American Cancer Society is encouraging men to discuss their risks of prostate cancer with their doctors and the possibility of screening. The American Cancer Society noted that cases of prostate cancer have continued to increase by...
PD-L1–High Metastatic NSCLC: First-Line Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Progression-Free Survival Endpoint
Sacituzumab govitecan-hziy plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS)...
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
Relapsed small cell lung cancer (SCLC) remains a major therapeutic challenge, with limited treatment options and poor outcomes after disease progression on platinum-based chemotherapy and immunotherapy. At the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on...
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
An 8-year update of the phase III ADAURA trial showed that adjuvant osimertinib continued to demonstrate an overall survival benefit over placebo in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study ...
Izalontamab Brenitecan Active in Previously Treated EGFR-Positive NSCLC
Izalontamab brenitecan (BL-B01D1), an EGFR x HER3 bispecific antibody, demonstrated antitumor activity and a tolerable safety profile, especially at higher dose levels, in patients with previously treated EGFR-mutated metastatic non–small cell lung cancer (NSCLC). These data from a randomized...
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, was compared with pembrolizumab as first-line treatment for patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC). Data from the prespecified interim analysis of the phase III HARMONi-2 trial were presented at the...
